Skip to content

ScienceNot yet confirmed elsewhere1 publisher2 min readPublished

SW.2 accounts for about 21% of reported COVID infections heading into winter

SW.2 accounts for about 21 percent of reported COVID-19 infections, ahead of XFG at 16 percent, while positive tests rise in the UK, Europe and the US. UK health officials say current data do not link any of the watched variants to significantly more severe illness.

The Scientist · Science desk

How we use AISend a correction

Illustration accompanying SW.2 accounts for about 21% of reported COVID infections heading into winter
Generated illustration

What happened

  • A routine COVID-19 test shows only whether the virus is present, and naming the variant takes genomic sequencing of the virus's genetic code.
  • BA.3.2, an Omicron BA.3 lineage nicknamed Cicada, is near 2 percent of cases but carries mutations that make vaccine escape more likely, according to Respiratory Therapy.
  • Discover says the rise is likely seasonal, driven by more indoor gatherings and fading immunity from the last vaccination.

Why it matters

  • contradiction The CDC's declining national trend runs against rising US positivity and regional upticks, so how heavy the US season looks depends on which geography a reader checks.
  • constraint Because shares come from sequencing only a fraction of positives, how precise the 2 percent BA.3.2 figure is depends on a sample size readers cannot check from this report.
  • exposure People with immune-affecting conditions, some cancers, autoimmune disease or organ-system disease carry more risk as circulation and admissions climb, whichever variant leads.

Every variant share in this report is a fraction of sequenced samples. Agencies pull a percentage of positive clinical tests for genomic sequencing and follow variant trends from those [6]. The three variants named add up to about 39 percent of reported infections, which leaves roughly 61 percent spread across other lineages [13]. SW.2 is described as one of the most dominant strains globally [1]. Its lead over XFG, which has circulated internationally for about a year, is about 5 percentage points [2][14].

Discover's case for sequencing is that a variant profile helps agencies judge how well current medical tools work against what is spreading [10]. In this report the immune-escape flag goes on BA.3.2, the smallest of the three [3]. The report does not include vaccine-effectiveness data for any of them. For SW.2 and XFG, the evidence on hand is their case shares and a severity comparison from the UK [1][2][7]. So the two largest named variants are described by how common they are, and the one flagged for evading vaccine immunity sits at about 2 percent [3].

The severity picture comes from the UK Health Security Agency. It says current data do not show these variants causing significantly more severe illness than others in circulation [7]. It also reports hospitalizations climbing alongside circulation [8]. Those two findings sit together comfortably. Admissions that rise with infections are what more cases at unchanged per-case severity would produce, and Discover interprets the UK data as overall activity rising, with no single variant driving worse disease [12]. A hospital count that tracks a case count cannot separate volume from virulence on its own. That separation needs the variant-by-variant comparison the agency describes [7].

Discover calls the seasonal explanation likely: more time indoors, and immunity from the last vaccination wearing off [16]. I think that is the right default reading while the UK severity data stay flat [7]. If one lineage, BA.3.2 or another, starts to account for the growth, the sequenced share of positives is where it would show first [6][10].

What to watch

  • WHO tracking of BA.3.2: a share climbing well above its current 2 percent would move vaccine escape to the center of the season.
  • A UKHSA update tying any one variant to more severe illness, or showing admissions rising faster than infections.
  • Whether the CDC's national COVID-19 trend turns upward to match the rising positivity reported for the US.

Clarity's read

What the record supports and how the coverage leans. The claims behind it follow.

Reality

Evidence40
Adoption
Insufficient
Hype gap+10
Incentives
Insufficient
Confidence40
Why these scores

Claim ledger

Ranked by verification strength, evidence, and original report placement.

  1. [1]

    The SW.2 variant accounts for around 21 percent of reported COVID-19 infections, making it one of the most dominant strains globally.

    ReportedSupportedSource: Discover MagazineView cited source
  2. [2]

    XFG, the Stratus variant, accounts for 16 percent and has been around internationally for about a year.

    ReportedSupportedSource: Discover MagazineView cited source
  3. [3]

    BA.3.2, also called Cicada and part of the Omicron BA.3 lineage, is at low case numbers (around 2 percent), but its mutation profile makes it more likely to evade vaccine immunity, according to Respiratory Therapy.

    ReportedSupportedSource: Discover Magazine, citing Respiratory TherapyView cited source

Sources

1 independent publisher whose own reporting we read for this story.

  1. discovermagazine.com

    1 article · October 9, 2026

    COVID-19 Cases Are Picking Up Again — These Are the Variants That Health Officials Are Watching

Share your take

Let Clarity write the post for you.

Signed-in readers get a short post drafted on this story in the register they choose — narrative, analytical, or a direct position — editable to the last word before it goes anywhere. The share buttons at the top of this story work without an account.

Topics and entities

Follow any of these and your For You feed starts watching them — no settings page required.

Topics

  • Respiratory Virus SeasonFollow
  • COVID-19 variant surveillanceFollow
Loading related stories